Paul Conkling
About
Paul Conkling is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, Paul Conkling has authored 97 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 68 papers in Oncology, 40 papers in Pulmonary and Respiratory Medicine and 27 papers in Molecular Biology. Recurrent topics in Paul Conkling's work include Lung Cancer Research Studies (23 papers), Lung Cancer Treatments and Mutations (21 papers) and Cancer Immunotherapy and Biomarkers (18 papers). Paul Conkling is often cited by papers focused on Lung Cancer Research Studies (23 papers), Lung Cancer Treatments and Mutations (21 papers) and Cancer Immunotherapy and Biomarkers (18 papers). Paul Conkling collaborates with scholars based in United States, France and Italy. Paul Conkling's co-authors include Donald Richards, Robert M. Jotte, Matthew D. Galsky, Markus F. Renschler, Jennifer Oliver, Craig H. Reynolds, James F. Fitzgibbons, Leonard M. Klein, Carol O’Hear and Joachim von Pawel and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.
In The Last Decade
Paul Conkling
92 papers receiving 1.7k citations
Peers
Paul Conkling
Yoshiyasu Nakamura Japan
Parisa Momtaz United States
Amit Panwalkar United States
Olaf Christensen United States
Carmelo Tibaldi Italy
John C. Araujo United States
Ki Y. Chung United States
G. Deplanque France
Frauke Bentzien United States
Carmen Kahatt Spain
Citations per year, relative to Paul Conkling Paul Conkling (= 1×)
peers
Yoshiyasu Nakamura
Countries citing papers authored by Paul Conkling
Since
Specialization
Citations
This map shows the geographic impact of Paul Conkling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Conkling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Conkling more than expected).
Fields of papers citing papers by Paul Conkling
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Paul Conkling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Conkling. The network helps show where Paul Conkling may publish in the future.
Co-authorship network of co-authors of Paul Conkling
This figure shows the co-authorship network connecting the top 25 collaborators of Paul Conkling. A scholar is included among the top collaborators of Paul Conkling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Conkling. Paul Conkling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Conkling, Paul, et al.. (2025). Real-world (RW) treatment (tx) patterns and clinical outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) in the US community setting.. Journal of Clinical Oncology. 43(5_suppl). 470–470.
2.
Uzzo, Robert G., Rituparna Bhattacharya, Manojkumar Bupathi, et al.. (2025). Real-world analysis of pembrolizumab utilization and characteristics of patients being prescribed treatment in early stage RCC.. Journal of Clinical Oncology. 43(5_suppl). 480–480.
3.
Arunachalam, Ashwini, et al.. (2024). Real-world treatment patterns and outcomes among unresectable stage III non-small cell lung cancer. PLoS ONE. 19(11). e0314156–e0314156.
4.
Goldschmidt, Jerome H., Lowell L. Hart, Jeffrey A. Scott, et al.. (2023). Real-World Outcomes of Trilaciclib Among Patients with Extensive-Stage Small Cell Lung Cancer Receiving Chemotherapy. Advances in Therapy. 40(10). 4189–4215.
5.
Goldschmidt, Jerome H., et al.. (2022). Trilaciclib Use and Chemotherapy-Induced Myelosuppression Among Patients with ES- SCLC in US Community Oncology Settings. 2(Supplement 2).
6.
Petrylak, Daniel P., Yohann Loriot, David R. Shaffer, et al.. (2021). Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study. Clinical Cancer Research. 27(12). 3360–3369.
7.
Bardia, Aditya, Virginia Kaklamani, Sharon Wilks, et al.. (2021). Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer. Journal of Clinical Oncology. 39(12). 1360–1370.
8.
Patel, Manish R., Salvatore Siena, George D. Demetri, et al.. (2020). O-3 Efficacy and safety of entrectinib in NTRK fusion-positive gastrointestinal cancers: Updated integrated analysis of three clinical trials (STARTRK-2, STARTRK-1 and ALKA-372-001). Annals of Oncology. 31. 232–233.
9.
Spira, Alexander I., Paul Conkling, Arvind Chaudhry, et al.. (2020). 1309P ARC-4: Efficacy and safety of AB928 plus carboplatin, pemetrexed and a PD-1 antibody in participants with metastatic non-small cell lung cancer (mNSCLC). Annals of Oncology. 31. S846–S846.
10.
Stewart, Tracy Murray, Daniel D. Von Hoff, Michael L. Fitzgerald, et al.. (2020). A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma. Cancer Chemotherapy and Pharmacology. 87(1). 135–144.
11.
Siena, Salvatore, George D. Demetri, Robert C. Doebele, et al.. (2019). Entrectinib in NTRK-fusion positive gastrointestinal cancers: integrated analysis of patients enrolled in three trials (STARTRK-2, STARTRK-1, and ALKA-372-001). Annals of Oncology. 30. iv134–iv134.
12.
Gadgeel, Shirish M., Rimas V. Lukas, Jerome H. Goldschmidt, et al.. (2018). Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study. Lung Cancer. 128. 105–112.
13.
Cortinovis, Diego, Joachim von Pawel, K. Syrigos, et al.. (2017). Immune-related adverse events (irAEs) in advanced NSCLC patients treated with atezolizumab: Safety population analyses from the Ph III study OAK. Annals of Oncology. 28. v468–v468.
14.
Pawel, Joachim von, K. Syrigos, Julien Mazières, et al.. (2017). Association between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the phase III study OAK. Annals of Oncology. 28. v469–v469.
15.
Beeram, M., Sara M. Tolaney, J. Thaddeus Beck, et al.. (2016). A phase 1b study of abemaciclib, an inhibitor of CDK4 and CDK6, in combination with endocrine and HER2-targeted therapies for patients with metastatic breast cancer. Annals of Oncology. 27. vi556–vi556.
16.
Rashidi, Armin, Paul Conkling, & Stephen I. Fisher. (2015). Acute promyelocytic leukemia following solid organ transplantation. Annals of Hematology. 95(1). 169–171.
17.
Smith, David A., Paul Conkling, Donald Richards, et al.. (2014). Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy. Cancer Immunology Immunotherapy. 63(8). 787–796.
18.
Saltz, Leonard B., Suprith Badarinath, Shaker R. Dakhil, et al.. (2011). Phase III Trial of Cetuximab, Bevacizumab, and 5-Fluorouracil/Leucovorin vs. FOLFOX-Bevacizumab in Colorectal Cancer. Clinical Colorectal Cancer. 11(2). 101–111.
19.
Camidge, D. Ross, Paul Conkling, Joe Stephenson, & Д. А. Шапиро. (2007). P3-138: A Phase I open label study of continuous oral treatment with BIBF 1120 together with carboplatin and paclitaxel treated patients with non–small cell lung cancer (NSCLC). Journal of Thoracic Oncology. 2(8). S738–S738.
20.
Reynolds, Craig H., Paul Conkling, Donald Richards, et al.. (2007). P2-292: A randomized Phase 3 trial of gemcitabine with or without carboplatin in performance status 2 (PS2) patients with advanced (stage IIIB with pleural effusion or IV) non-small-cell lung cancer (NSCLC). Journal of Thoracic Oncology. 2(8). S688–S688.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Yoshiyasu Nakamura Breakdown of academic impact, for papers by Parisa Momtaz Breakdown of academic impact, for papers by Amit Panwalkar Breakdown of academic impact, for papers by Olaf Christensen Breakdown of academic impact, for papers by Carmelo Tibaldi Breakdown of academic impact, for papers by John C. Araujo Breakdown of academic impact, for papers by Ki Y. Chung Breakdown of academic impact, for papers by G. Deplanque Breakdown of academic impact, for papers by Frauke Bentzien Breakdown of academic impact, for papers by Carmen Kahatt